Paul M O'Byrne Selected Research

3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)

10/2021	The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada.
1/2021	Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.
1/2021	The management of mild asthma.
1/2020	What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?
10/2017	The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials.
1/2017	The paradoxes of asthma management: time for a new approach?
1/2005	Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul M O'Byrne Research Topics

Disease

160	Asthma (Bronchial Asthma) 01/2022 - 01/2002
44	Inflammation (Inflammations) 01/2022 - 01/2002
24	Respiratory Hypersensitivity 01/2022 - 02/2002
17	Eosinophilia 01/2022 - 07/2002
9	Cough 01/2022 - 07/2015
8	Chronic Obstructive Pulmonary Disease (COPD) 08/2015 - 08/2009
5	Allergic Rhinitis 01/2022 - 08/2002
5	Airway Remodeling 01/2022 - 11/2002
3	Chronic Cough 01/2022 - 01/2020
3	Pneumonia (Pneumonitis) 09/2015 - 07/2006
2	Hypersensitivity (Allergy) 01/2017 - 08/2003
2	Infections 01/2014 - 01/2012
2	Rhinitis 03/2004 - 08/2002
1	Tuberculosis (Tuberculoses) 01/2022
1	Dysphonia (Spastic Dysphonia) 06/2021
1	Dyspnea (Shortness of Breath) 01/2020
1	Gastroesophageal Reflux (GERD) 01/2020
1	Bronchitis 01/2020
1	Stroke (Strokes) 01/2019
1	Occupational Asthma 05/2017

Drug/Important Bio-Agent (IBA)

65	AllergensIBA 01/2022 - 01/2002
60	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 07/2002
36	Budesonide (Pulmicort)FDA LinkGeneric 01/2022 - 07/2002
27	Formoterol Fumarate (Oxis)FDA Link 01/2022 - 01/2004
15	CytokinesIBA 10/2020 - 07/2002
13	SteroidsIBA 01/2020 - 01/2003
13	Interleukin-5 (Interleukin 5)IBA 01/2016 - 07/2002
12	Methacholine Chloride (Methacholine)FDA Link 01/2021 - 11/2002
10	fluticasone furoate FDA Link 01/2020 - 06/2013
10	Interleukin-13IBA 01/2019 - 04/2004
9	Terbutaline (Brethaire)FDA LinkGeneric 12/2021 - 01/2005
9	Immunoglobulin E (IgE)IBA 03/2017 - 08/2002
8	vilanterolIBA 01/2020 - 06/2013
7	Bronchodilator Agents (Bronchodilators)IBA 12/2021 - 08/2015
7	Formoterol Fumarate Drug Combination Budesonide FDA Link 12/2021 - 01/2004
7	3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)IBA 10/2021 - 01/2005
7	anti-IgE antibodiesIBA 01/2017 - 08/2002
6	Leukotriene Antagonists (Leukotriene Receptor Antagonists)IBA 12/2021 - 01/2004
6	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2017 - 02/2007
6	Monoclonal AntibodiesIBA 01/2017 - 03/2009
6	Pharmaceutical PreparationsIBA 08/2016 - 11/2002
5	Prednisone (Sone)FDA LinkGeneric 10/2020 - 04/2003
4	Capsaicin (Zostrix)FDA Link 01/2021 - 03/2017
4	Fluticasone (Cutivate)FDA LinkGeneric 01/2020 - 02/2011
4	InterleukinsIBA 01/2019 - 07/2002
4	Biological ProductsIBA 01/2019 - 06/2008
4	GlucocorticoidsIBA 06/2018 - 01/2016
4	Interleukin-33IBA 01/2017 - 06/2015
4	Omalizumab (Xolair)FDA Link 01/2017 - 08/2002
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 04/2009
3	Thymic Stromal LymphopoietinIBA 01/2017 - 05/2014
3	Salmeterol Xinafoate (Serevent)FDA Link 06/2014 - 02/2011
3	Interleukin-18 ReceptorsIBA 01/2014 - 01/2013
3	OvalbuminIBA 01/2012 - 07/2002
3	LeukotrienesIBA 09/2009 - 07/2002
3	Interleukin-4 (Interleukin 4)IBA 07/2006 - 04/2004
2	Histamine (Histamine Dihydrochloride)FDA Link 01/2021 - 05/2002
2	Interleukin-17 (Interleukin 17)IBA 01/2018 - 01/2014
2	AlarminsIBA 01/2017 - 01/2017
2	Cholinergic Antagonists (Anticholinergics)IBA 08/2016 - 01/2012
2	mepolizumabIBA 01/2016 - 03/2009
2	PeriostinIBA 01/2016 - 09/2015
2	Humanized Monoclonal AntibodiesIBA 01/2016 - 01/2013
2	Proteins (Proteins, Gene)FDA Link 01/2014 - 09/2002
2	AntigensIBA 01/2014 - 01/2012
2	Immunoglobulins (Immunoglobulin)IBA 01/2013 - 06/2008
2	ciclesonide FDA Link 02/2011 - 08/2005
2	Interleukin-10 (Interleukin 10)IBA 11/2008 - 02/2002
2	Messenger RNA (mRNA)IBA 05/2008 - 09/2002
2	montelukast (Singulair)FDA Link 09/2006 - 11/2002
2	ChemokinesIBA 03/2005 - 08/2003
2	pranlukastIBA 07/2004 - 04/2004
2	Histamine Antagonists (Antihistamines)IBA 03/2004 - 07/2002
1	VaccinesIBA 01/2022
1	AerosolsIBA 01/2022
1	A 7 (A-7)IBA 06/2021
1	Muscarinic AntagonistsIBA 06/2021
1	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 01/2021
1	Antigen-Antibody Complex (Immune Complex)IBA 10/2020
1	AutoantibodiesIBA 10/2020
1	Peptides (Polypeptides)IBA 01/2020
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2020
1	Opioid Analgesics (Opioids)IBA 01/2020
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2020
1	prednylidene (Pred)IBA 01/2020
1	Purinergic P2X3 ReceptorsIBA 01/2020
1	Pregabalin (Lyrica)FDA Link 01/2020
1	BariumIBA 01/2017
1	Pepsin A (Pepsin)IBA 01/2017
1	2- hydroxy- N,N- dimethyl- 3- (2- ((1- (5- methylfuran- 2- yl)propyl)amino)- 3,4- dioxocyclobut- 1- enylamino)benzamideIBA 12/2016
1	N- (2- (2,3- difluoro- 6- benzylthio)- 6- (3,4- dihydroxybutan- 2- yloxy)pyrimidin- 4- yl)azetidine- 1- sulfonamideIBA 10/2016

Therapy/Procedure

58	Therapeutics 01/2022 - 07/2002
6	Nebulizers and Vaporizers (Inhaler) 06/2021 - 01/2004
4	Drug Therapy (Chemotherapy) 01/2017 - 10/2007
2	Aftercare (After-Treatment) 01/2021 - 11/2008
2	Precision Medicine 01/2017 - 01/2016
2	Emergency Treatment 01/2017 - 01/2009
1	Airway Management 01/2022
1	Language Therapy (Language Training) 01/2020
1	Long-Term Care 01/2019